← Back to headlines
FDA Review Meeting Scheduled for Compass Pathways' Depression Drug COMP360
An upcoming FDA review meeting will determine the future of Compass Pathways' depression drug candidate COMP360, as the company awaits regulatory feedback on its potential treatment.
25 Mar, 18:10 — 25 Mar, 18:10
Sources
Showing 1 of 1 sources
Related Stories
Study Reveals Elderly More Vulnerable to Extreme Heat Than Previously Thought
3h ago
Nollywood Actor Ogogo Hassan's Daughters Seek Help for Father's Stage 4 Cancer
6h ago
Cancer Survivor Erin Races Against Time for Chance of Motherhood
7h ago
West Nile Fever Spreads in North Macedonia and Serbia, Causing Deaths
7h ago